EQ logo

EQ Equillium, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.37
-0.05 (-3.52%)

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpo…

Market Cap: $86.87Mequilliumbio.com

Price

No data yet.

Social Signal Score

38
5d
—
30d
30
1 mentions
—
60d
38
5 mentions
—
90d
47
7 mentions
—
news: 7

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 1Sell 0Strong Sell 0
Avg price target$6+338.0%
Low $5Median $6High $7
Current Consensus

Revenue

$0.00
$0.00$5.25M$10.51M$15.76M
Jun 2017Jun 2026

Analyst Estimates

FY2025
$-0.41
$-0.42–$-0.40
2 analysts
FY2026
$-0.20
$-0.21–$-0.19
7 analysts
FY2027
$-0.23
$-0.34–$-0.19
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Bruce D. Steel
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
2.04
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
15.09
equilliumbio.com